"the Most Expensive Shares," Supremacy And More About Who Is "false" - The Hai

After consecutive three-day slump, Hai Purui yesterday announced "not found" messages

need to correct, the two drugs were reported to hold similar FDA-certified companies remain silent

LONDON May 14 news: yesterday 9:30, "in the history of the most expensive shares," Hai Purui not opening on time; the third consecutive day, with a total drop of 25.6% of the "break" the trend, linked to the company board of directors out of the "unusual fluctuations in stock notice." Bulletin said: early disclosure of information not found there is need to correct, supplement the Department, not found in public media coverage of the Company may be or already have a greater impact stock price undisclosed material information ... ...

In various media have questioned Hai Purui prospectus, as I suspected false statement, notice that the "not found", what is the response of self-confidence, or the persistence of cheating?

"Most expensive" in the April 23, 2010, Hai Purui determine IPO Price: 148 yuan. "Shares the history of the most expensive," was born.

Lay its "most expensive" status is sought after institutions: the road show site, "more than 100 people in the room to sit, the back is also full of people," the popular high-level brokerage has wiped away many memories; China Department WANG Ya-wei 1 star fund managers "rarely before seen such a good pharmaceutical companies" set off the body collectively excited, Hai Purui the inquiry was to identify the basic range of 70 times to 90 times price-earnings ratio between the brokers and even the most excited Times inquiry out of more than 200 high, the highest even to 250, so that for the first time the Commission issued new shares to establish a "window guidance" --- the issue price shall not exceed 200; April 19 to 4 21, Hai Purui the lead underwriter in the electronic platform of investment securities received 133 inquiries single organization to declare the 373 placing objects in the initial inquiry report, the final 211 to share about 800 million shares Haipu Rui, issue price up to 148 yuan. This scene, in the past six months of the SME Board and the GEM IPO has never seen.

Institutions is not crazy. The "rarely seen" a good pharmaceutical companies, "good" in its "unique": prospectus said the company is "zero defects" result FDA site review by the United States, and invited to participate in USP Heparin Sodium standard revision. With APP signed an exclusive supplier and the exclusive purchasing supplementary statement, allowing the company to become the U.S. high-dose standard heparin preparations the only supplier of bulk drugs ... ...

"Only" the suspect Haipu Rui's "unique" in the IPO price of 148 yuan was questioned after release.

4 since 23 of the week, several media outlets published reports that: get FDA certification of domestic raw material drug companies far more than heparin Hai Purui 1. Currently, FDA has been reported with heparin sodium API certified domestic enterprises generally have Yantai Dongcheng Biochemicals pharmaceutical company, Changzhou Qianhong biochemical pharmaceutical companies, pharmaceutical companies, Nanjing Health Friends biochemistry, and obtained the certification of the time 2009.

Hai Purui of information is the only FDA "distortion" in judging the value of the company how much? According to Hai Purui described in the prospectus, the next longer period, the company will heparin API products as the dominant strategy will not change, heparin sodium API will play a decisive role in company; in Heparin API market adverse changes in the company not to market new products or the formation of market circumstances, may be a major impact on its results of operations. In addition, Hai Purui also mentioned that if other domestic enterprises certified by the U.S. FDA, it will likely reduce the company's competitive advantage, and thus impact our business. This means that, FDA certification is related only to the future Hai Purui of bargaining power, heparin product capacity and stability of the status of the industry an important factor.

"Unique" set Haipu Rui's "core competencies" and "monopolistic advantages", which is more than the value of broker determine Hai Purui important basis for investments: In most brokerage recommendation report issued by Inquiry both stressed the "Hai Purui product heparin in antithrombotic and anticoagulant drugs do not substitute" and "Hai Purui standard high-dose heparin in the United States only bulk drugs formulations suppliers" both "the only sex. "

by: gaga

POST COMMENT

Your Success Is Accelerated By Good Support And Tools Witness the wonder satibo brings to the size and length of your weapon A Case Assessment And A Normal Assessment Fun Attachments and Charms for Your Keychain Pre and Post Workout: What To Eat Before Workout and After Wokrout Surface Drainage, Whether There Are Gaps Caused Flooding In The City - Water Supply And Drainage, Know The Insider Secrets Of Stock Exchange Use A Toro Snow Thrower And Save Your Back BJJ in My Eyes - Achieving a BJJ Black Belt, and the Responsibilities You Must Accept with it!! Part 3 Learn The Ropes In Stock Trading To Earn Big The Challenge of Aloneness and Loneliness for Independent Consultants The Pros And Cons Associated With Private Label Resell Rights In September over the same period of beef and mutton prices rose